Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL5964784 | 0.85 | GRIA1 (0.43) | GRIA1GRIA3GRIA2GRIA4MEN1 | |
| SCHEMBL29262695 | 0.79 | GRIA1 (0.49) | GRIA1GRIA3GAAGRIA2GRIA4 | |
| SCHEMBL13319909 | 0.79 | GRIA1 (0.41) | GRIA1GRIA3GAAGRIA2GRIA4 | |
| SCHEMBL5290687 | 0.79 | GRIA1 (0.41) | GRIA1GRIA3GAAGRIA2GRIA4 | |
| SCHEMBL6809086 | 0.79 | CACNA1F (0.33) | — | |
| SCHEMBL8609634 | 0.75 | GRIA1 (0.40) | GRIA1GRIA3GAAGRIA2GRIA4 | |
| SCHEMBL68800 | 0.75 | — | — | |
| SCHEMBL2575298 | 0.75 | — | — | |
| Bromide SCHEMBL7200266 | 0.74 | — | — | |
| SCHEMBL5062987 | 0.72 | GRIA1 (0.39) | GRIA1GRIA3GAAGRIA2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066323-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING COMBINATIONS OF AN AMPA/KAINATE ANTAGONISTIC COMPOUND AND AN INHIBITOR OF A MULTIDRUG RESISTANCE PROTEIN | NeuroSearch AS (DK) | 2009-06-10 | — | — | EP | claimed |
| WO-2008031831-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING COMBINATIONS OF AN AMPA/KAINATE ANTAGONISTIC COMPOUND AND AN INHIBITOR OF A MULTIDRUG RESISTANCE PROTEIN | NEUROSEARCH A/S (DK) | 2008-03-20 | — | — | WO | claimed |
| US-7192931-B2 | Treatment of demyelinating diseases | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-03-20 | — | — | US | claimed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| EP-4188382-A1 | ADMINISTRATION OF MODULATORS OF 5-HT AND/OR AMPA RECEPTORS FOR TREATING NEUROLOGICAL CONDITIONS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022023813-A1 | ADMINISTRATION OF MODULATORS OF 5-HT AND/OR AMPA RECEPTORS FOR TREATING NEUROLOGICAL CONDITIONS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2022-02-03 | — | — | WO | disclosed |
| CN-113425690-A | Perampanel orally disintegrating tablet and preparation method thereof | 北京万全德众医药生物技术有限公司 | 2021-09-24 | — | — | CN | disclosed |
| CN-106389367-B | Perampanel coated tablet pharmaceutical composition | 杭州朱养心药业有限公司 | 2020-12-18 | — | — | CN | disclosed |
| CN-107616969-B | Rapidly disintegrating pharmaceutical composition of Perampanel tablets | 杭州朱养心药业有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20180318279-A1 | TOPICAL COMPOSITIONS PROVIDING PAIN RELIEF AND METHODS OF USE THEREOF | RUSH UNIVERSITY MEDICAL CENTER (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170312308-A1 | XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS | THE MCLEAN HOSPITAL CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| WO-1998027097-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS NEUROPROTECTIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0837854-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0832074-A1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040649-A1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040651-A1 | ALKYL AMINE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995007887-A1 | INDOLE DERIVATIVES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS | GLAXO S.P.A. (IT) | 1995-03-23 | — | — | WO | disclosed |
| EP-0486621-A4 | NMDA OXIDIZING AGENTS FOR PROTECTING NEURONS FROM INJURY | — | 1993-03-31 | — | — | EP | disclosed |
| EP-0486621-A1 | NMDA OXIDIZING AGENTS FOR PROTECTING NEURONS FROM INJURY | The Children's Medical Center Corporation (US) | 1992-05-27 | — | — | EP | disclosed |
| WO-1991002810-A1 | NMDA OXIDIZING AGENTS FOR PROTECTING NEURONS FROM INJURY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1991-03-07 | — | — | WO | disclosed |